Skip to content
MarketScale
‹ Back to IndustriesSciences

AI Failed At Writing Sci-Fi. Here’s Why Publishers May Just Want Them to Succeed

Recently, science fiction magazine Clarkesworld was forced to close submissions for authors after being flooded with stories written by AI tools. While it was clear that the AI failed at writing sci-fi, this failure pointed towards larger problem: AI-assisted plagiarism. Neil Clarke, the editor of Clarkesworld, said the amount of spam the magazine typically…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Darren Campo · Alex DetailAsimov’s Science FictionChatgptClarkesworld
Share

Key takeaways

01

Recently, science fiction magazine Clarkesworld was forced to close submissions for authors after being flooded with stories written by AI tools.

02

While it was clear that the AI failed at writing sci-fi, this failure pointed towards larger problem: AI-assisted plagiarism.

03

Neil Clarke, the editor of Clarkesworld, said the amount of spam the magazine typically…

Recently, science fiction magazine Clarkesworld was forced to close submissions for authors after being flooded with stories written by AI tools. While it was clear that the AI failed at writing sci-fi, this failure pointed towards larger problem: AI-assisted plagiarism.

Neil Clarke, the editor of Clarkesworld, said the amount of spam the magazine typically receives has increased drastically since ChatGPT was launched. The culprits, he believes, are not authors themselves — but rather, people who want to take advantage of the sci-fi community’s higher rates for authors and always-open submission windows.

Clarkesworld is not the only sci-fi magazine facing this problem. Asimov’s Science Fiction has also been receiving similar AI submissions. Some of them were so obviously written by AI that they actually had the same title.

While the AI tools failed at writing sci-fi, they are likely to improve with time. However, some experts believe the publishing world need not be worried, as improved technology and new cutting edge tools for creating or publishing written content has generally had a positive impact on readers and writers. Darren Campo, Senior Vice President of Programming and Content Strategy for The Food Network and Cooking Channel, Adjunct Assistant Professor at the NYU Stern School of Business, and author of the sci-fi series Alex Detail, tells us why anything (even disruptive technology) is great for the publishing world if it increases readership.

Darren’s Thoughts:

Science fiction magazines that publish short stories are now being inundated by stories written by AIs like Chat GPT. This is according to a recent article from The New York Times where they spoke to the editors at sci-fi magazines like Clarkesworld and Asimov’s Science Fiction. Now, according to the editors so far, these stories aren’t very good. They’re pretty easy to spot. They read more like a list of facts in a simple story format rather than something that a writer developed in his/her craft has written. However, it really won’t be long before AI is able to generate stories that are interesting to some people to read. So, how does this impact the publishing world?

Well, first we should ask, ‘How does this impact the reader? How has technology impacted readership in the past?’ A couple of big examples are the technologies that enabled for self-publishing. With self-publishing, we had books about subjects and characters that were not widely written about before, and that was great for readers. Another technology that allowed for the distribution of fan fiction over the internet led to things like 50 Shades of Grey, which was the highest selling book of its decade and inspired thousands of book clubs, movies about those book clubs, and other movies. So, that was also generally a net positive for both the reader and the publishing world.

So as this disruptive technology unfolds, it will eventually be a positive for the reader and anything that’s good and increases readership is great for the publishing world as well. As a science fiction writer myself, I am really looking forward to seeing how this all unfolds over the next few years.”

Article written by Aarushi Maheshwari.

About the author

Darren Campo
Darren CampoAdjunct Professor of Media & Technology

Darren Campo is an Adjunct Professor of Media & Technology at NYU's Stern School of Business. He's a seasoned producer, media executive, and bestselling novelist. Campo has held significant roles in programming, development, and production for networks such as Food Network, Cooking Channel, TruTV, and Court TV. Darren played a pivotal role in the creation of and programming development for TruTV of TimeWarner, and has been involved in the production and development of hundreds of shows. He is also the author of novels like "Alex Detail’s Revolution" and "Disappearing Spell."

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

Darren Campo
Darren Campo

Adjunct Professor of Media & Technology

Darren Campo is an Adjunct Professor of Media & Technology at NYU's Stern School of Business. He's a seasoned producer, media executive, and bestselling novelist. Campo has held significant roles in programming, development, and production for networks such as Food Network, Cooking Channel, TruTV, and Court TV. Darren played a pivotal role in the creation of and programming development for TruTV of TimeWarner, and has been involved in the production and development of hundreds of shows. He is also the author of novels like "Alex Detail’s Revolution" and "Disappearing Spell."